What are the key insights from JPM 2025?

Liberi Group had the privilege of attending the 2025 J.P. Morgan Healthcare Conference in San Francisco and has returned to the Netherlands energized by the exciting developments and valuable connections we made. The conference once again showcased a dynamic mix of emerging science, strategic business moves, and forward-looking predictions for the biotech and pharmaceutical industries. From therapeutic innovations to financial outlooks, industry leaders gathered to share insights on what the coming year—and beyond—may bring.

One of the most prominent themes was the continued focus on anti-obesity therapeutics and on oncology, neurology, and immunology treatments reflecting a strong market demand and ongoing clinical innovations. Additionally, many discussions focused on making gene editing technologies commercially viable. Stakeholders stressed the need to refine delivery mechanisms to ensure both safety and efficacy in clinical programs.

Another hot topic at this year’s conference was the potential resurgence of large-scale mergers and acquisitions particularly after J&J announced the acquisition of Intra-Cellular for $14.6 billion. While many conference-goers discussed the likelihood of increased consolidation in CNS, rare disease, and oncology companies during 2025, some also noted that many early-stage biotechs face serious challenges in securing sufficient funding or partnerships. As a result, some predicted a “quiet demise” for those unable to show meaningful progress to their pipelines throughout the year. This undercurrent of uncertainty could lead to selective “megadeal” acquisitions, where only the most promising targets find solid footing. That said, many industry leaders believe these “megadeal” acquisitions won’t remain sustainable, and that by mid-2025 we may see a shift back to smaller, more traditional $10–$25 million series raises.

Finally, attendees discussed potential regulatory changes under the new US administration that could lead to a more favorable environment for private equity investments in healthcare. While such developments remain subject to policy decisions and broader market forces, a more flexible regulatory framework may open the door to new financing opportunities and innovative business models in the months to come.

Overall, the 2025 JPM Healthcare Conference reinforced the industry’s adaptability and resilience, highlighting significant progress in areas like gene editing and next-generation therapeutics. At the same time, it underscored the shifting nature of venture capital, the potential reemergence of large-scale M&A deals, and the operational challenges of bringing advanced therapies to market. Despite the complexities, the event served as an invaluable platform for leaders to connect, collaborate, and shape a more innovative and sustainable future for healthcare.

In conclusion, as the biotech landscape continues to evolve, Liberi Group stands ready to help our clients navigate this dynamic environment. Our team looks to combines our industry knowledge with a strategic, forward-looking approach, in areas such as fundraising, partnership development, and commercialization. By leveraging insights from the conferences we attend and our extensive network, we aim to empower our clients tackle challenges, seize opportunities, and achieve great outcomes in the year ahead!